319 related articles for article (PubMed ID: 11305380)
21. Short term methotrexate therapy in psoriasis.
Kumar B; Handa S; Kaur I
Indian J Med Res; 1994 Dec; 100():277-80. PubMed ID: 7829167
[TBL] [Abstract][Full Text] [Related]
22. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients.
Cabello Zurita C; Grau Pérez M; Hernández Fernández CP; González Quesada A; Valerón Almazán P; Vilar Alejo J; Carretero Hernández G
J Dermatolog Treat; 2017 Aug; 28(5):401-405. PubMed ID: 28001499
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
25. Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion.
Yélamos O; Català A; Vilarrasa E; Roé E; Puig L
Dermatology; 2014; 229(4):306-9. PubMed ID: 25401478
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate treatment in 13 children with severe plaque psoriasis.
Collin B; Vani A; Ogboli M; Moss C
Clin Exp Dermatol; 2009 Apr; 34(3):295-8. PubMed ID: 19175782
[TBL] [Abstract][Full Text] [Related]
27. Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: Real-world data from a nationwide cohort study in Taiwan.
Tang KT; Chen YM; Chang SN; Lin CH; Chen DY
J Am Acad Dermatol; 2018 Oct; 79(4):652-658. PubMed ID: 29753054
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up.
Malatjalian DA; Ross JB; Williams CN; Colwell SJ; Eastwood BJ
Can J Gastroenterol; 1996 Oct; 10(6):369-75. PubMed ID: 9193771
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
[TBL] [Abstract][Full Text] [Related]
30. Systemic methotrexate therapy for psoriasis: past, present and future.
Dogra S; Mahajan R
Clin Exp Dermatol; 2013 Aug; 38(6):573-88. PubMed ID: 23837932
[TBL] [Abstract][Full Text] [Related]
31. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
Salim A; Tan E; Ilchyshyn A; Berth-Jones J
Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
[TBL] [Abstract][Full Text] [Related]
32. Use of methotrexate in patients with psoriasis.
Kuhn A; Ruland V; Patsinakidis N; Luger TA
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S138-44. PubMed ID: 21044448
[TBL] [Abstract][Full Text] [Related]
33. Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial.
Radmanesh M; Rafiei B; Moosavi ZB; Sina N
Int J Dermatol; 2011 Oct; 50(10):1291-3. PubMed ID: 21950300
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis.
Attwa EM; Elkot RA; Abdelshafey AS; Hafez AR
Dermatol Ther; 2019 Sep; 32(5):e13051. PubMed ID: 31381231
[TBL] [Abstract][Full Text] [Related]
35. [Apparent worsening of psoriasis lesions revealing methotrexate overdosage].
Haber R; Baroudjian B; Battistella M; Bagot M; Petit A
Ann Dermatol Venereol; 2018 Feb; 145(2):104-108. PubMed ID: 28917574
[TBL] [Abstract][Full Text] [Related]
36. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
Reich K; Signorovitch J; Ramakrishnan K; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
J Am Acad Dermatol; 2010 Dec; 63(6):1011-8. PubMed ID: 20933301
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis.
Akhyani M; Chams-Davatchi C; Hemami MR; Fateh S
J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1447-51. PubMed ID: 20384673
[TBL] [Abstract][Full Text] [Related]
38. A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia.
Ng LC; Lee YY; Lee CK; Wong SM
Int J Dermatol; 2013 Jan; 52(1):102-5. PubMed ID: 23278617
[TBL] [Abstract][Full Text] [Related]
39. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients.
vanDooren-Greebe RJ; Kuijpers AL; Buijs WC; Kniest PH; Corstens FH; Nagengast FM; de Boo T; Willems JL; Duller P; van de Kerkhof PC
Br J Dermatol; 1996 Mar; 134(3):481-7. PubMed ID: 8731673
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis.
Yesudian PD; Leman J; Balasubramaniam P; Macfarlane AW; Al-Niaimi F; Griffiths CE; Burden AD; Warren RB
J Drugs Dermatol; 2016 Mar; 15(3):345-9. PubMed ID: 26954320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
